To the Editor.—
We read the article of Mueller et al reporting successful treatment of the neuroleptic malignant syndrome (NMS) with bromocriptine mesylate (1983;249:386). At the time this article appeared, we were in the process of evaluating the effect of bromocriptine in a patient with features of the NMS, who eventually responded favorably.
Report of a Case.—
A 48-year-old chronic schizophrenic receiving treatment with monthly 1.5-mL (37.5-mg) intramuscular injections of fluphenazine deconoate was admitted to the hospital on Dec 24, 1982, because of nausea, vomiting, and generalized seizures. The family stated that the patient was consuming large amounts of water and complaining of thirst before his admission.The patient had a temperature of 35.5 °C, BP of 140/72 mm Hg, a regular pulse rate of 80 beats per minute, and respirations of 20/min. The remainder of the general physical examination results were unremarkable. The neurologic examination results were remarkable for
Dhib-Jalbut S, Hesselbrock R, Brott T. Treatment of the Neuroleptic Malignant Syndrome With Bromocriptine. JAMA. 1983;250(4):484–485. doi:10.1001/jama.1983.03340040028016
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.